Chemical Development Industries (CID)

    Chemical Development Industries (CID)

    EEGX:CID
    10.00
    EGP
    0.00
    (0.00%)
    No data availableFinancial data will appear here once available

    Capital Structure

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Working Capital

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Growth Rates

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Revenue

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Earnings Per Share

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Dividends Per Share

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business
    Chemical Industries Development (CID), also known as CID Pharmaceuticals, is an Egypt-based pharmaceutical manufacturing company engaged in the research, development, formulation, production, and commercialization of human pharmaceuticals, veterinary medicines, dietary supplements, and specialized healthcare products. Founded in 1947 and headquartered in Giza, Egypt, the company operates as a subsidiary of the state-owned Holding Company for Pharmaceuticals (HoldiPharma) under the Ministry of Public Business Sector. The company manufactures and distributes products across diverse therapeutic classes and dosage forms, including solid dosage forms such as effervescent tablets, film-coated tablets, chewables, and hard gelatin capsules; oral liquids, including pediatric syrups, suspensions, oral drops, and rehydration solutions; sterile injectables, encompassing aqueous ampoules, oily hormonal injections, and sterile vials; semi-solid and topical formulations, such as medicated creams, ointments, and dermatological gels; and respiratory and ENT treatments, including nasal drops and decongestants. CID's core product portfolio encompasses prominent commercial brands such as Aspocid for antiplatelet and analgesic therapies; Cidophage for diabetes and glycemic management; Amoxicid for broad-spectrum antibacterial treatments; Rhinex for nasal congestion; Sulfozinc for nutritional and pediatric supplementation; and Agiolax for gastrointestinal care, in addition to dedicated lines for maternal and child healthcare, family planning, cardiovascular disease, and metabolic disorders. The company serves public health programs, private pharmacies, hospitals, and institutional healthcare providers throughout Egypt, while maintaining extensive export operations across Arab, Middle Eastern, and African markets through its dual manufacturing complexes located in Giza and Assiut. In recent strategic developments, CID secured a temporary listing on the Egyptian Exchange (EGX) with an issued capital of EGP 400 million divided into 40 million shares, marking a pivotal preparatory step within Egypt's national privatization and state-asset offering program. Furthermore, the company has executed comprehensive modernization and renovation programs across its Giza and Assiut facilities to upgrade its specialized sterile hormonal ampoule and effervescent production lines in full compliance with updated Good Manufacturing Practice (GMP) standards set by the Egyptian Drug Authority and international health bodies, while expanding regional export partnerships and contract manufacturing capabilities.